会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • METHOD FOR TAILORING ADMINISTRATION OF DRUGS BY QUANTITATION OF MRNA
    • 通过MRNA定量定量化药物的方法
    • WO2006045053A3
    • 2007-05-18
    • PCT/US2005037925
    • 2005-10-20
    • HITACHI CHEMICAL CO LTDHITACHI CHEMICAL RES CT INCMITSUHASHI MASATO
    • MITSUHASHI MASATO
    • C12Q1/68
    • G01N33/57426C12Q1/6886C12Q2600/158G01N2333/4724
    • The present invention discloses a method for tailoring drug protocols to individual patients based on the levels of marker mRNA measured in leukocytes after stimulation of whole blood of the patient with candidate drugs. A method of measuring a patient's responsiveness to a drug is disclosed that includes exposing whole blood of the patient to the drug for 7 hours or less; after the exposure, measuring the amount of an mRNA associated with an effect of the drug in blood cells; and identifying responsiveness to the drug based on the results of the measurement, wherein a change in the amount of the mRNA indicates the patient's responsiveness to the drug. The amount of mRNA measured in the blood cells may be compared with the level of mRNA present in the cells before exposure or with the level of mRNA present in cells exposed for the same amount of time to a control vehicle. Marker mRNAs useful in the present invention include mRNAs encoding the gene product of the p21, BAX, PUMA, NOXA, and IL-2 genes. The method may be employed for patients with, among other conditions, cancer or diseases or conditions requiring immunosuppression.
    • 本发明公开了一种基于在患有候选药物的患者的全血刺激后在白细胞中测量的标记物mRNA水平对个体患者定制药物方案的方法。 公开了一种测量患者对药物的反应性的方法,其包括将患者的全血暴露于药物7小时以下; 在暴露后,测量与药物在血细胞中的作用相关的mRNA的量; 并且基于测量结果确定对药物的反应性,其中mRNA量的变化表示患者对药物的反应性。 可以将在血细胞中测量的mRNA的量与暴露前细胞中存在的mRNA水平或存在于暴露于对照载体相同时间量的细胞中的mRNA水平进行比较。 可用于本发明的标记mRNA包括编码p21,BAX,PUMA,NOXA和IL-2基因的基因产物的mRNA。 该方法可用于患有除其他病症之外的患有癌症或需要免疫抑制的疾病或病症的患者。
    • 5. 发明申请
    • METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
    • 基于神经细胞和刺激白血病细胞中mRNA表达谱的免疫应答预防神经病变的方法
    • WO2006133399A9
    • 2007-03-01
    • PCT/US2006022427
    • 2006-06-08
    • HITACHI CHEMICAL RES CT INCHITACHI CHEMICAL CO LTDMITSUHASHI MASATO
    • MITSUHASHI MASATO
    • C12Q1/70G01N33/00G01N33/53
    • G01N33/505C12Q1/6806C12Q1/6886C12Q2600/118C12Q2600/158G01N33/574
    • Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse.
    • 肿瘤坏死因子(TNF)能够通过与癌细胞表面的特异性TNF受体相互作用诱导细胞凋亡。 由于TNF配体和受体的多个成员存在于每个超家族中,所以存在超过300种不同的配体 - 受体组合。 活化的血液白细胞产生TNF作为对癌症的免疫应答的一部分,以及产生趋化因子以吸引其他白细胞到该部位。 公开了当全血暴露于作为免疫系统相互作用的模型的热聚集的IgG或抗T细胞受体抗体时,检测血白细胞中各种TNF超家族亚型和趋化因子mRNA的显着诱导的方法。 在TNF亚型和趋化因子诱导中观察到显着的个体与个体差异。 由于外周血白细胞是抗癌免疫细胞的供应,所以在个体化的癌症免疫治疗中定量适当的TNF配体和趋化因子在血液中的离体诱导性将是有用的。 如果肿瘤质量小,如早期隐形转移性病变,适当的TNF攻击可能足以防止复发。
    • 7. 发明申请
    • PRIMER GENERATION ROLLING CIRCLE AMPLIFICATION
    • 主发电轧制圆盘放大
    • WO2006074162A3
    • 2006-08-31
    • PCT/US2006000086
    • 2006-01-04
    • HITACHI CHEMICAL CO LTDHITACHI CHEMICAL RES CT INCMURAKAMI TAKU
    • MURAKAMI TAKU
    • C12Q1/68C07H21/04C12P19/34
    • C12P19/34C12Q1/6844C12Q2531/125
    • A method of amplifying a nucleic acid is provided which comprises: generating a first nucleic acid primer from a first nucleic acid sequence; combining the first nucleic acid primer with a first polymerase and a first circular nucleic acid probe, wherein the first circular nucleic acid probe contains at least one antisense sequence to a second nucleic acid sequence and at least one antisense sequence to the first nucleic acid primer; producing at least one repeat of a sequence copy of the first circular nucleic acid probe by rolling circle amplification using the first polymerase, wherein the sequence copy contains at least the second nucleic acid sequence; generating a second nucleic acid primer from the second nucleic acid sequence; combining the second nucleic acid primer with a second polymerase and a second circular nucleic acid probe, where the second circular nucleic acid probe contains at least one antisense sequence to the second nucleic acid primer; and producing at least one repeat of a sequence copy of the second circular nucleic acid probe by rolling circle amplification using the second polymerase. The method may be employed to detect molecules of interest such as nucleic acid sequences, DNA methylation, single nucleotide polymorphisms (SNP), proteins and posttranslational modifications. Furthermore, a ribbon probe is provided that comprises a circular nucleic acid probe and a nucleic acid lock probe, wherein: the nucleic acid lock probe contains at least a cleavable linker, and the circular nucleic acid probe and the lock probe are unable to dissociate without cleaving the cleavable linker.
    • 提供了扩增核酸的方法,其包括:从第一核酸序列产生第一核酸引物; 将第一核酸引物与第一聚合酶和第一环状核酸探针组合,其中所述第一环状核酸探针含有与第二核酸序列的至少一个反义序列和与第一核酸引物的至少一个反义序列; 通过使用第一聚合酶的滚环扩增产生第一环状核酸探针的序列拷贝的至少一个重复序列,其中序列拷贝至少包含第二核酸序列; 从第二核酸序列产生第二核酸引物; 将所述第二核酸引物与第二聚合酶和第二环形核酸探针组合,其中所述第二环形核酸探针含有与所述第二核酸引物至少一个反义序列; 并通过使用第二聚合酶的滚环扩增产生第二环状核酸探针的序列拷贝的至少一个重复序列。 该方法可用于检测感兴趣的分子,如核酸序列,DNA甲基化,单核苷酸多态性(SNP),蛋白质和翻译后修饰。 此外,提供了包含环状核酸探针和核酸锁定探针的带状探针,其中:核酸锁定探针至少含有可切割的接头,并且环状核酸探针和锁定探针不能解离 切割可切割的接头。
    • 10. 发明申请
    • IONIC POLYMER DEVICES AND METHODS OF FABRICATING THE SAME
    • 离子聚合物装置及其制造方法
    • WO2007084796A3
    • 2008-07-17
    • PCT/US2007001853
    • 2007-01-23
    • HITACHI CHEMICAL RES CT INCHITACHI CHEMICAL CO LTDWU YONGXIANLI YANGYANG
    • WU YONGXIANLI YANGYANG
    • C08J5/20
    • H01M4/8642C08J5/20F03G7/005H01B1/122
    • An embodiment provides an ionic polymer device comprising two extended electrode layers comprising a plurality of conductive particles, wherein the plurality of conductive particles form a concentration gradient in each of the two extended electrode layers, an ionic polymer dielectric layer between two extended electrode layers, and at least one conductive layer on outer surfaces of two extended electrode layers. Another embodiment provides an ionic polymer device comprising a polymer composite with a plurality of surface features on two opposite surfaces, and at least one conductive layer on each of said two opposite surfaces. One embodiment provides a method of making an ionic polymer device, comprising forming a partially cured polymer-metallic salt layer, reducing the metallic salt to form a plurality of metal particles, thereby forming a first extended electrode layer and a second extended electrode layer at and near opposite surfaces of the ionic polymer device.
    • 一个实施方案提供了一种离子聚合物装置,其包含两个包括多个导电颗粒的延伸电极层,其中多个导电颗粒在两个延伸电极层中的每一个中形成浓度梯度,在两个延伸电极层之间形成离子聚合物电介质层, 在两个延伸的电极层的外表面上的至少一个导电层。 另一个实施方案提供了一种离子聚合物装置,其包括在两个相对表面上具有多个表面特征的聚合物复合物,以及在所述两个相对表面中的每一个上的至少一个导电层。 一个实施方案提供了一种制备离子聚合物装置的方法,包括形成部分固化的聚合物金属盐层,还原金属盐以形成多个金属颗粒,由此在其上形成第一延伸电极层和第二延伸电极层, 靠近离子聚合物装置的相对表面。